We are dedicated to restoring health and hope to patients with rare diseases. Our deep understanding of the PPi-Adenosine Pathway drives our mission to develop innovative therapeutics that address the underlying causes of debilitating conditions such as ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis and ossification of the posterior longitudinal ligament (OPLL).
With decades of clinical, scientific, regulatory, commercial, and financial expertise, we are committed to pushing boundaries and transforming patient lives. Our focus is on creating novel therapies that provide hope and improve outcomes for those affected by these challenging diseases. Together, we aim to make a meaningful impact on the lives of patients and their families.
Senior Leadership
Doug Treco, Ph.D.
CEO, Chairman of Board of Directors
Douglas Treco, Ph.D., currently serves as Chief Executive Officer and has served as the chairman of our board of directors since May 2020. Dr. Treco was Co-Founder, President, and CEO of Ra Pharmaceuticals, Inc., a biotechnology company focused on peptide and small molecule inhibitors of the complement pathway. The company was acquired in April 2020 by UCB S.A.. Its lead program, Zilbrysq® , has been approved for the treatment of myasthenia gravis in all major markets. Dr. Treco was CEO of Alchemab Therapeutics from April 2021 to April 2022. Previously, he co-founded Transkaryotic Therapies, Inc. (TKT), which was acquired in 2005 by Shire plc. In his position as Senior Vice President of Research and Development, he established and directed TKT’s gene activation and protein production efforts, which led to the approval of Dynepo™, Replagal®, Elaprase®, and Vpriv®. Dr. Treco is a member of the Board of Directors of CRISPR Therapeutics AG. He is also a scientific advisor to Lightstone Ventures. Dr. Treco was a visiting scientist in the Department of Molecular Biology at Massachusetts General Hospital and a lecturer in genetics at Harvard Medical School from 2004 to 2007. He holds a BA in Biology from the University of Delaware, a PhD in Biochemistry and Molecular Biology from the State University of New York at Stony Brook and performed post-doctoral research at the Salk Institute for Biological Studies and Massachusetts General Hospital.
Petra Duda, M.D., Ph.D.
Chief Medical Officer
Petra Duda, M.D., Ph.D. was appointed Chief Medical Officer of Inozyme Pharma in May 2025, bringing more than two decades of global leadership in clinical development, medical affairs, and regulatory strategy, with deep expertise in rare and ultra-rare diseases.
Dr. Duda joined Inozyme in November 2024 and most recently served as Global Development Lead at UCB, where she oversaw the Zilbrysq® (zilucoplan) program and led it through global regulatory approvals for the treatment of generalized myasthenia gravis. She joined UCB through its acquisition of Ra Pharmaceuticals, where she led clinical development for a portfolio of complement pathway inhibitors.
Earlier in her career, Dr. Duda held senior roles at Sarepta Therapeutics, where she played a pivotal role in the development and approval of Exondys 51® for Duchenne muscular dystrophy, and at Biogen Idec, where she led neurology development programs. She also held positions in medical affairs and drug safety at Boehringer Ingelheim.
Dr. Duda is board certified in both Neurology and Pharmaceutical Medicine. She earned her M.D. and Ph.D. in molecular biology and biochemistry from the University of Bern.
Gayle Gironda
Senior Vice President and Chief People Officer
Gayle Gironda joined Inozyme in July 2021 and serves as our senior vice president and Chief People Officer. She has more than 20 years of experience in organizational design, talent recruitment, performance culture, planning and leadership development.
Ms. Gironda offers a deep knowledge of life sciences, stemming from her work with large multinational pharmaceutical organizations as well as small biotech companies. She previously served as vice president, human resources, global hematology and global market access at Bristol Myers Squibb (BMS), playing a key role integrating the Hematology Business Unit as part of the company’s acquisition of Celgene. Additionally, she supported the Global Market Access, Pricing and Health Economics and Outcomes Research (HEOR) teams through post-acquisition strategy, organizational design and talent alignment. Before joining Celgene in 2018 as vice president, human resources, global franchises, Ms. Gironda was executive director, HR, commercial operations at Alexion Pharmaceuticals. Her previous experience also includes leadership roles in human resources and operations for small-to-mid-sized companies such as Watson/Actavis, Jerini Ophthalmic, Inc. and Eyetech Pharmaceuticals. Ms. Gironda received a B.A. in liberal studies from SUNY Purchase and has completed additional graduate coursework in social-organizational psychology at Columbia University, Teachers College.
Kurt Gunter, M.D.
Senior Advisor
Kurt Gunter, M.D. has served as a key member of Inozyme’s leadership team since joining the company in June 2022. He now contributes as a senior advisor, following his tenure as Chief Medical Officer. Dr. Gunter brings over 30 years of experience in regulatory affairs, clinical development, and government relations, with deep expertise in cell and gene therapy.
Prior to joining Inozyme, he served as Chief Medical Officer, Cell Therapy, and Head of Regulatory Affairs at Athenex. He previously held the role of Chief Medical Officer at Kuur Therapeutics (formerly Cell Medica), where he oversaw medical affairs, clinical operations, and regulatory affairs.
Earlier in his career, Dr. Gunter held senior positions at Hospira, Inc., including Vice President of Clinical Development and Global Medical Director for Hematology-Oncology. He also played a key role in the development of enzyme replacement therapies during his time at Transkaryotic Therapies, Inc., where he helped lead the global regulatory strategy for Replagal, approved for Fabry disease. Additional biotech experience includes roles at Zymequest and ViaCell.
Dr. Gunter has contributed meaningfully to the broader field of cellular therapy, serving as President of the International Society for Cellular Therapy (ISCT), where he helped advance global understanding of clinical, regulatory, and commercial pathways for innovative therapies.
Earlier in his career, Dr. Gunter worked at the U.S. Food and Drug Administration (FDA) as a Medical Officer in the Center for Biologics and was appointed Acting Deputy Director of the Division of Cell and Gene Therapy. He also served for five years on the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee.
Dr. Gunter earned his M.D. from the University of Kansas School of Medicine and holds a B.S. in Biological Sciences with Distinction from Stanford University. His postdoctoral training was completed at Johns Hopkins University and the U.S. National Institutes of Health.
Yves Sabbagh, Ph.D.
Senior Vice President and Chief Scientific Officer, Chair of the Scientific Advisory Board
Yves Sabbagh, Ph.D., is our senior vice president and chief scientific officer, joining Inozyme in October 2020. Dr. Sabbagh brings to Inozyme more than 25 years of experience in rare genetic disorders and mineral metabolism with responsibilities leading to the identification and evaluation of novel therapeutic approaches and translating them into clinical candidates through IND.
Prior to joining Inozyme, Dr. Sabbagh served as global head of rare renal and musculoskeletal diseases research at Sanofi’s rare disease and neurological unit, advancing a pipeline of drug candidates using multiple therapeutic modalities, including proteins and small molecules. Prior to that executive role, he held scientific roles of increasing responsibility at Sanofi and Genzyme Corporation spanning endocrine, renal and rare bone diseases including driving the strategy for rare bone indications such as osteogenesis imperfecta and achondroplasia and managing research in disease mechanisms, and target discovery/validation. Prior to his corporate experience, he was an instructor at the Harvard Medical School in the Endocrine unit. Dr. Sabbagh has co-authored more than 40 peer-reviewed publications and book chapters and is a member of several scientific societies. Dr. Sabbagh has won various awards for his work throughout his career. Dr. Sabbagh received a B.Sc. in biochemistry from McGill University, an MSc in microbiology from Université Laval and a Ph.D. in biology from McGill University and performed post-doctoral research at Harvard Medical School in the Endocrine Unit at Massachusetts General Hospital.
Sanjay S. Subramanian, M.S., MBA
CFO and Head of Business Development
Sanjay Subramanian joined Inozyme as Chief Financial Officer in March 2022. He brings to Inozyme over 20 years of corporate finance, capital markets, and business development expertise. Prior to joining Inozyme, Mr. Subramanian served as CFO and head of corporate development at Ocugen, Inc., where he led the company’s finance, investor relations, and business development functions.
At Ocugen, Mr. Subramanian was instrumental in improving its capital structure, raising over $200 million, and leading transformative collaboration. Prior to Ocugen, he held roles of increasing responsibility at Aralez Pharmaceuticals, most recently as CFO, and played a key role in the Aralez formative transaction and its listing on Nasdaq and TSX. Mr. Subramanian also previously held positions of increasing responsibility at Bausch Health Companies, including playing a key role in the acquisition, financing, and post-merger integration of Bausch & Lomb. Before Bausch Health, Mr. Subramanian was part of General Motors’ finance leadership rotation program and served as the Managing Director and Treasurer at its Korea division as his last role. He received an MBA from the MIT Sloan School of Management, a Master of Science from both the Massachusetts Institute of Technology (MIT) and The Ohio State University, and a Bachelor of Technology from the Indian Institute of Technology.
Matt Winton, Ph.D.
Senior Vice President and Chief Operating Officer
Matthew Winton, Ph.D., joined Inozyme as Senior Vice President and Chief Operating Officer in April 2023. Dr. Winton most recently served as senior vice president and head of the Multiple Sclerosis franchise for Biogen’s US organization. Previously, he was the head of Spinal Muscular Atrophy (SMA) franchise in the US, where he was responsible for setting strategic direction for the infant, pediatric, and adult markets. Dr. Winton also served as Director, Payer and Channel Marketing, where he was responsible for the development and execution of pricing, access, and reimbursement strategies across various therapeutic franchises. In particular, he helped successfully prepare the organization for the approval and launch its first orphan disease drug, SPINRAZA™.
Dr. Winton began his career in management consulting, where he provided strategic and operational support to senior and executive level clients ranging from small biotech startups to large multinational pharmaceutical companies. Dr. Winton earned his Bachelor of Science in biology and psychology from York University in Toronto, Ontario, Canada. He holds a Ph.D. in neuroscience from the University of Montreal, an MBA in healthcare management from Boston University, and did a postdoctoral fellowship in neurodegenerative disease at the University of Pennsylvania.
David Thompson, M.A., M.S., Ph.D.
Senior Advisor, Member of Scientific Advisory Board
David Thompson is currently a senior advisor. Dr. Thompson previously served on our leadership team as chief development officer in 2021, after serving as our senior vice president and chief scientific officer from 2018 to 2020. In his former role, Dr. Thompson was responsible for scientific research as the company built its proprietary pipeline of investigational therapies, beginning with INZ-701.
He has more than 30 years of experience designing and leading research and development programs focused on bone disorders and phosphate regulation. Prior to joining Inozyme Pharma, Dr. Thompson was a founder and president of Azure Biotech, where he was responsible for the development of a novel formulation of lasofoxifene, a non-steroidal selective estrogen receptor modulator used for the prevention and treatment of osteoporosis and the treatment of vaginal atrophy. Previously, Dr. Thompson held executive positions in clinical research and drug development in multiple biopharma companies, including Alexion Pharmaceuticals, where he led the clinical development of asfotase alfa for the treatment of hypophosphatasia; and Pfizer, where he oversaw the osteoporosis research and frailty discovery groups. While at Merck Research Labs, he conducted preclinical work and participated in the early clinical development of alendronate for the treatment of osteoporosis. Dr. Thompson received his M.A. from the University of Montana and both his M.S. and Ph.D. from the University of Connecticut.